Erenumab
Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
| Trade Name | Aimovig |
|---|---|
| Common Name | Erenumab |
| Indication | migraine disorders |
| Drug Class | Monoclonal antibodies: fully human, neural indications |
